Should You Worry About the Short Interest in Synta Pharmaceuticals (SNTA)? - Tale of the Tape

By
A A A

Many investors appear to be quite bearish Synta Pharmaceuticals Corp. ( SNTA ) especially if you look at the percentage of the float that is sold short for this stock. Currently, 34.9% of the float is sold short, suggesting an extreme level of bearishness for SNTA.

However, it is worth noting that earnings estimates have actually been moving higher for the company, despite the pessimism. Thanks to these rising estimates, we actually have a Zacks Rank #2 (Buy) on SNTA , so we clearly don't believe in the negativity surrounding this firm, and are instead looking for shares of SNTA to move higher in the weeks ahead.



SYNTA PHARMACT (SNTA): Free Stock Analysis Report


To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: SNTA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

122,762,267
  • $15.81 ▼ 1.43%
62,277,320
  • $8.50 ▼ 6.80%
58,664,622
  • $128.46 ▼ 1.50%
48,473,163
  • $25.99 ▲ 0.39%
36,433,239
  • $5.12 ▲ 7.34%
35,593,669
  • $6.63 ▲ 5.41%
30,823,989
  • $16.68 ▼ 3.02%
30,676,302
    $2.08 unch
As of 2/27/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com